Introduction
Bladder cancer (BC) is an increasingly important international public health problem. BC is nearly 3-4 times more common in men than in women. [1] The incidence rate of BC, which varies among ethnic groups and geographic region, has increased dramatically in recent years. The incidence in India is comparatively low and it is 3.2 in males and 0.7 in females/100,000 people. [2, 3] Risk factors for the development of BC can be classified into three subsets; genetic and molecular abnormalities, chemical or environmental exposures and chronic irritation. [4] The process of tumor formation and regulation involves a complex combination of genetic, environmental and life-style factors. Complex diseases such as cancer, including BC, have been hypothesized to arise due to the effect of many low-risk gene variants that collectively increase disease risk. [3] Single nucleotide polymorphisms (SNPs) are the most common sequence variations in the human genome and they involve only a single base mutation and can affect coding sequences, splicing and transcription regulation.
SNPs can comprehensively reflect genomic hereditary
and variation with a large quantity, high density, wide distribution and typical representation. Therefore, SNPs BACKGROUND AND AIM: p73, a novel P53 homolog and plays an important role in modulating cell cycle control, apoptosis and cell growth while P21, functions to negatively control the cell cycle. P53 up regulates p21 expression in response to deoxyribonucleic acid damage leading to cell cycle arrest at G1 checkpoint. In the present study, we are targeting p21 codon 31 and p73 gene variants of G4C14-to-A4T14 (Exon 2) polymorphism for bladder cancer (BC) risk in North Indians. MATERIALS AND METHODS: The above gene variants of P21 and P73 were assessed in the case-control study comprising of 200 BC cases and 200 healthy controls of the same age, gender and similar ethnicity. Genotyping was performed by polymerase chain reaction (PCR) restriction fragment length polymorphism method and PCR-based confronting two-pair primers (PCR with CTPP). RESULTS: The variant genotype of p73Exon 2 polymorphism showed significant risk for BC (p = 0.014). While combining with heterozygous genotype, variant genotype of p73Exon2 showed a significant association with BC risk (p = 0.010). While in case of p21 codon31 showed no significant association for BC risk at genotypic level. Significant association between p73Exon2 polymorphism and smoking was observed for BC risk. Furthermore, gene combination analysis revealed that AT/AT-Ser/Ser is associated with risk for BC. Variant genotype of P73Exon2 was associated with reduced risk of recurrence (p = 0.039) in superficial BC patients receiving Bacillus Calmette-Guerin treatment thus showing least survival (log rank = 0.029).
CONCLUSION:
Our study provided evidence that the p73 G4C14 > A4T14 (Exon2) polymorphisms were associated with higher risk of BC in North Indian population. may play increasingly important roles in screening for the gene mutations and susceptibility to oncogenic factors. [5, 6] The p73 protein is a P53 homolog encoded by a polymorphic gene located on 1p36-33, mapping on a region often deleted in a prostate and lung cancer. [7, 8] p73
protein activates several P53-responsive genes involved in cell cycle control, deoxyribonucleic acid (DNA) repair and apoptosis and inhibits cell growth in a P53-like manner by inducing apoptosis. [9] Extensive molecular analyses of p73 in various tumors suggested that mutations in this gene are rare because they occur in <2% of all cancers. Furthermore, increased p73 expression was found in human malignancies associated with p53 mutations, suggesting p73 may act as a tumor suppressor with some of the same functions as p53 or may compensate the loss of p53 function. [10] It is unknown whether the alteration of p73 expression has any genetic basis such as sequence variations or polymorphisms.
At least 17 single-nucleotide polymorphisms have been The Ser31Arg polymorphism also known as p21 codon31
is located in the highly conserved region of p21 and may encode functionally distinct proteins. It is encoded by the CDKN1A gene located on chromosome 6 (6p21.2) and has a p53 transcriptional regulatory motif Thus, most reports focus on genetic variants of p21 and genotypes of some functional polymorphisms have shown to be associated with a high-risk of different types of cancer such as ovarian cancer and breast cancer. [11, 12] Alteration in this gene may adversely affect the regulation of cellular proliferation and increase the susceptibility for cancer. P21WAF1/CIP1 have been speculated to change its function and the high-risk genotypes have been reported to be associated with different cancers including carcinomas of the breast, ovary, [11, 12] cervical cancer [13] and prostate carcinoma. [14] The most frequently investigated polymorphism of p21 is Ser31Arg (rs1801270C > A), with a base change from C to A resulting in a non-synonymous serine to arginine substitution in the protein [15] causing a loss of the BlPl restriction site and affecting the DNA binding zinc finger motif. [16] Hence, it is likely that Ser31Arg polymorphism may result in the alteration of expression and/or activity, thereby affecting susceptibility to cancer.
Many molecular epidemiological studies have been conducted to evaluate the effect of the Ser31Arg polymorphism on cancer risk. The results, however, remain conflicting and the underlying heterogeneity between studies still needs to be explored.
Given the major roles that p21 codon 31 and p73
G4C14-to-A4T14 Exon 2 play in cell cycle checkpoint regulation, we hypothesized that polymorphisms in the two genes may modify individual susceptibility to BC.
Therefore, we evaluated the association between SNPs of p21 and p73 and BC susceptibility in a hospital-based case-control study in North Indian population.
Materials and Methods

Study subjects
The BC patients in this analysis were enrolled from an on-going case-control study of BC, which started patient recruitment in 2010. All enrolled patients were 
Epidemiology data collection
The demographic details were obtained by interviewing each individual in cases and controls. The response rate for the interview was 75% for the subjects. Individuals who smoked once a day for more than 5 years were defined as smokers. The individuals who had never smoked in their lifetime were regarded as non-smokers.
At the conclusion of the interview, a 5 ml of a blood sample was drawn into coded vials.
Clinical data collection
The demographic and clinical characteristics of the patients are presented in 
Genotyping
Genomic DNA was extracted from peripheral blood lymphocytes by salting out method. [18] Polymorphisms in P21 codon31 were analyzed using polymerase chain reaction (PCR) -restriction fragment length polymorphism. The full detail of the primers and PCR conditions were for p21 codon 31, [13] whereas PCR-based confronting two-pair primers (CTPP) (PCR with CTPP) genotyping was performed for the p73 G4C14-to-A4T14 (GC/AT) Exon 2 polymorphism. Primer sequences and PCR conditions used have been described elsewhere [19] and genotyping was done on 2% agarose gel and 10% polyacrylamide gel using molecular weight markers and visualized after staining with ethidium bromide. Positive and negative controls were used in each genotyping assay and 10% of the samples were randomly selected and run in duplicates with 100% concordance. The results were reproducible with no discrepancy in genotyping.
Statistical analysis
The power of the study was calculated using Quanto software, version 1.0 (Freely available from: http:// hydra.usc.edu/gxe) with input of following variables: Case-control study design, significance level (alpha) >0.05 (2 sided), model of inheritance was log additive, allele frequency was 0.28 and the genetic effect for odds ratio (OR) was 1.65 or greater. The present study achieved 80% of the statistical power. The goodness-of-fit Chi-square test was used to analyze any deviation from the Hardy-Weinberg equilibrium in controls. A binary logistic regression model was used to estimate the risk as the OR at the 95% confidence interval (CI). Bonferroni's correction was applied in case of multiple comparisons using the formula p c = p × n (P c -represents corrected value where n is the number of comparisons performed). The statistical analysis was done using the Statistical Package for Social Sciences software, version 15.0 (SPSS, Chicago, IL) and P < 0.05 was considered statistically significant.
Results
Characteristics of subjects
A total of 200 controls and 200 cases were recruited for this study. There was no significant age difference between the cases (58.5 ± 12.4 years) and the controls (56. 8 ± 10.8 years) (P = 0.117). The cases had significantly higher percentage of smokers (69.9%) than the controls (22.5%) (P = 0.001). The demographic details of the study subjects and clinical characteristics of the patients are presented in Table 1 .
Genotypic frequency of p73Exon2 gene and p21 codon 31 gene polymorphisms in BC
The genotype and allele frequencies of p73Exon2 and p21 codon 31 gene polymorphism in healthy individuals (controls) and BC patients are presented in Table 2 . The genotype frequencies of controls were in Hardy Weinberg equilibrium. We observed a significant association in the variant genotype of p73Exon2 polymorphism (P = 0.014 OR = 3.80, 95% CI, 1.31-11.01) with BC risk, whereas no association with p21 codon 31 was observed. However, combined heterozygous and variant genotype showed risk for BC (P = 0.010 OR = 1.58, 95% CI, 1.12-2.23).
Association of p73Exon2 gene and p21 codon 31 genotypes with smoking
We evaluated the gene smoking interaction to study the modulation of BC risk with respect to p73 and p21 codon 31. The patients were grouped as non-smokers and smokers. In case of p73 G4C14 > A4T14 gene, the hetero genotype GC/AT was associated with higher risk of BC (P = 0.017; OR, 3.02; 95% CI, 1.22-7.46). However, no significant association was observed in case of p21 codon 31 [ Table 3 ]. Table 4 ].
Modulation of genotype variants and outcome after BCG immunotherapy
To analyze the association of gene polymorphisms of p73Exon2 and p21 codon 31 and risk of recurrence in NMIBC patients, further analysis was restricted to NMIBC patients only (n = 149). The median follow-up of NMIBC patients was 14 months (3-60 months).
We analyzed the association of genotypes and risk of recurrence after BCG immunotherapy. We grouped patients into BCG treated (n = 78) and non-treated (n = 71) as these were patients of low grade tumors and did not require BCG immunotherapy. The patients of "BCG group" with variant genotype (AT/ AT) of p73 G4C14 > A4T14 were observed to have high-risk of recurrence (p = 0.039; HR, 3.04)
[ Table 5 ]. Subsequently, Kaplan-Meier analysis of p73 G4C14 > A4T14 showed a higher recurrence free survival 46 months of GC/GC genotype as compared with 38 months of GG/AT genotype carrying patients While variant genotype AT/AT showed least survival with 25 months (log rank P = 0.029) [ Figure 1 ]. p21 codon 31 gene polymorphism were not associated with risk of recurrence free survival.
Gene combination effect between p73 and P21 polymorphism gene polymorphism
To analyze the combined effect of these polymorphisms,
we conducted gene-gene interaction analysis. Gene combination between p73 and p21 showed a significant risk of BC (AT/AT-Ser/Ser p = 0.022; OR, 3.43; 95% CI;
1.19-9.86) with 3.43 fold risk [ Table 6 ].
Discussion
The p53 gene and its encoded protein are related with the regulation of cell cycle, cellular growth and apoptosis. Recent studies have revealed that several genetic polymorphisms may play important roles in the pathogenesis of BC such as Survivin -31G/C [20] and CCL2 I/D [21] in north Indian population. In this hospital-based case-control study, we found that the variant genotypes (GC/AT + AT/AT) and variant allele of p73 were associated with an increased risk of BC. Although how this p73 polymorphism influences the development of cancer is unknown, one possible explanation is that the GC to AT change may lead to the formation of a stem-loop structure and so may influence the translation efficiency of p73. [22] Another possibility is that the p73 polymorphism is in linkage disequilibrium with other functional polymorphisms that affect either the expression or activity levels of enzymes involved in tumorigenesis. [23] However, a study in breast cancer showed contrary result that the GC/GC genotype of P73Exon2 is significantly associated with poor prognosis in breast cancer. [24] In another study indicated that P73Exon2 AT/AT homozygotes appear to be protected in oesophageal cancer. [25] Consistent with these contradictory results, several studies have correlated with an increased risk of various cancers, including the head and neck cancer [19, 26] and lung cancer. [27] Our study showed no significant association of p21 codon 31 gene polymorphism with BC risk. Although recent studies suggest that the p21 polymorphism is likely to contribute to genetic susceptibility to cancer in case of Lung carcinoma. [28] Some studies including ours found no association between the polymorphism and cancer risk along with study in lung cancer. [29] However, our observation was in line with some of study nasopharyngeal carcinoma [30] and with esophageal squamous cell carcinoma showing no association with disease. [31, 32] This discrepancy could be due to different carcinogenic mechanisms among different cancer types, as well as differences in the underlying genetic backgrounds and/or environmental and social factors in different populations studied. A study in Korean population showed that codon 31 Ser/Se homozygote of the p21 gene could be a risk factor for the development of cervical adenocarcinoma associated with high-risk human papillomavirus. [13] The same result was found in case of esophageal cancer showing p21 codon 31 Ser homozygosity conferred risk for the process of developing esophageal cancer. [32] However, there were contradictory result in case of BC an individual possessing one allele of arginine form in p21 codon 31 has a higher risk of developing BC than the serine form. [33] Arg/Arg genotype was found to have an increased risk of developing prostate cancer and Benign
Prostatic Hyperplasia compared with those having the Ser/Ser genotype. [34] We also analyzed gene-gene combination to evaluate the synergistic effect on BC. A significant association prognostic value for clinical diagnosis and the outcome is of great implication. In addition, findings such as these will lead to the development of genetic risk prediction panels for eventual classification of patients who may most benefit from targeted surveillance or prevention strategies.
